| Drug Name |
Nilutamide |
| Drug ID |
BADD_D01568 |
| Description |
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. |
| Indications and Usage |
For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2). |
| Marketing Status |
approved; investigational |
| ATC Code |
L02BB02 |
| DrugBank ID |
DB00665
|
| KEGG ID |
D00965
|
| MeSH ID |
C021277
|
| PubChem ID |
4493
|
| TTD Drug ID |
D0SN9T
|
| NDC Product Code |
59981-030; 76055-0012; 62559-173; 66993-212; 53220-123; 59212-111 |
| UNII |
51G6I8B902
|
| Synonyms |
nilutamide | 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione | RU 23908 | RU-23908 | Anandron | RU 23908-10 | Nilandron |
